ACADIA Pharmaceuticals Inc. (ACAD)

NASDAQ: ACAD · Real-Time Price · USD
17.26
-0.76 (-4.22%)
Dec 12, 2024, 4:00 PM EST - Market closed
-4.22%
Market Cap 2.87B
Revenue (ttm) 929.24M
Net Income (ttm) 128.51M
Shares Out 166.39M
EPS (ttm) 0.78
PE Ratio 22.23
Forward PE 31.63
Dividend n/a
Ex-Dividend Date n/a
Volume 1,221,597
Open 17.92
Previous Close 18.02
Day's Range 17.25 - 18.19
52-Week Range 14.15 - 32.59
Beta 0.41
Analysts Buy
Price Target 26.44 (+53.19%)
Earnings Date Nov 6, 2024

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin tha... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 27, 2004
Employees 598
Stock Exchange NASDAQ
Ticker Symbol ACAD
Full Company Profile

Financial Performance

In 2023, ACADIA Pharmaceuticals's revenue was $726.44 million, an increase of 40.45% compared to the previous year's $517.24 million. Losses were -$61.29 million, -71.62% less than in 2022.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $26.44, which is an increase of 53.19% from the latest price.

Price Target
$26.44
(53.19% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees ...

1 day ago - Business Wire

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead...

3 days ago - Business Wire

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growt...

15 days ago - Seeking Alpha

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and c...

16 days ago - Business Wire

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside ...

21 days ago - Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted ind...

27 days ago - Business Wire

Acadia Pharmaceuticals: Proving The Naysayers Wrong

Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also...

4 weeks ago - Seeking Alpha

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript

5 weeks ago - Seeking Alpha

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024. “The success of Acadia's two growing commer...

5 weeks ago - Business Wire

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Vou...

5 weeks ago - Business Wire

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. f...

2 months ago - Business Wire

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett syndrom...

2 months ago - Business Wire

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board ...

2 months ago - Business Wire

Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals

TOKYO--(BUSINESS WIRE)-- #DrugDiscovery--Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals.

3 months ago - Business Wire

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

Shares of Acadia trended lower this year due to Daybue's poor quarterly sales performance, and also due to Nuplazid's failure in the phase 3 trial in schizophrenia patients. The full-year guidance on ...

3 months ago - Seeking Alpha

Ryan Reynolds Announces More to Parkinson's® Campaign

SAN DIEGO--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson's disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-f...

4 months ago - Business Wire

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, ...

4 months ago - Business Wire

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communic...

4 months ago - Seeking Alpha

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2024. “In the second quarter of 2024, Acadia delivere...

4 months ago - Business Wire

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Tuesday, August 6, 2024, after the close of the U.S. fina...

5 months ago - Business Wire

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from two open-label extension studies, LILAC-1™ and LILAC-2™, which showed...

5 months ago - Business Wire

Acadia Pharmaceuticals: Back In The Buy Zone

Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $...

6 months ago - Seeking Alpha

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett S...

6 months ago - Business Wire

New Millie Report Finds Hybrid Maternal Healthcare Model Improve Deliveries, Patient Engagement and Cost Savings

BERKELEY, Calif.--(BUSINESS WIRE)--Millie, a modern maternity clinic, today revealed promising maternal health outcomes from the first cohort of more than 150 births from its hybrid model that combine...

Other symbols: ALLG
6 months ago - Business Wire

Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments

ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful FDA-approved commercial products, Nuplazid and Daybue. Nuplazid, indicated for Parkin...

6 months ago - Seeking Alpha